{
    "clinical_study": {
        "@rank": "6477", 
        "arm_group": {
            "arm_group_label": "Fentanyl matrix"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring\n      satisfaction with pain treatment after administering fentanyl matrix in patients whose pain\n      was not controlled sufficiently with the previous analgesic use in real practice at the\n      investigator's discretion."
        }, 
        "brief_title": "Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study", 
        "completion_date": {
            "#text": "July 2009", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "This is a multi-center, open-label (all people know the identity of the intervention),\n      prospective (the patients are identified and then followed forward in time for the outcome\n      of the study) observational study. The study population comprises patients who are admitted\n      to a study center during the study period and are receiving a strong oral long-acting opioid\n      analgesic but deemed to control pain insufficiently. Since this study is an observational\n      study conducted in real practice, a dose of fentanyl matrix should be adjusted depending on\n      an individual patient's response at the investigator's discretion. However, for the patients\n      whose pain is not sufficiently controlled despite administration of strong long-acting\n      opioid analgesics, the minimum initial dose will be fentanyl matrix 75 micrograms/h and the\n      investigator can adjust dosage according to the degree of the patients' pain control during\n      the 9 days of the study period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients complaining of cancer pain which requires administration of long-acting\n             opioid analgesics\n\n          -  Patients whose pain is not sufficiently controlled despite administration of strong\n             long-acting opioid analgesics\n\n          -  Patients who are deemed to need an initial minimum dose of fentanyl matrix 75\n             micrograms/h\n\n          -  Patients who signed the informed consent form\n\n        Exclusion Criteria:\n\n          -  Patients with a history of or current drug or alcohol abuse\n\n          -  Childbearing women who are pregnant or likely to be pregnant during the study period\n             and men who are neither infertile nor willing to refrain from sexual relations but\n             whose partner does not conduct an effective contraception\n\n          -  Patients who are unable to use a transdermal system due to skin disease\n\n          -  Patients with history of hypersensitivity to opioid analgesics\n\n          -  Patients who are not eligible for the study participation based on warnings,\n             precautions and contraindications in the package insert of the study drug at the\n             investigator's discretion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who are admitted to a study center during the study period and are receiving a\n        strong oral long-acting opioid analgesic but deemed to control pain insufficiently."
            }
        }, 
        "enrollment": {
            "#text": "636", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816503", 
            "org_study_id": "CR015778", 
            "secondary_id": [
                "FENPAI4084", 
                "FEN-KOR-5027"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Fentanyl matrix", 
            "description": "This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fentanyl"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pain", 
            "Cancer pain", 
            "Fentanyl", 
            "Fentanyl matrix", 
            "Opioid analgesic"
        ], 
        "lastchanged_date": "March 20, 2013", 
        "number_of_groups": "1", 
        "official_title": "High-dose Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The overall satisfaction is measured by a 5-point scale. Patients' answers are rated as: \"very satisfied\", \"satisfied\", \"fair\", \"dissatisfied\", or \"very dissatisfied\".", 
            "measure": "The percentage of patients who are very satisfied or satisfied with the pain treatment after the study drug administration", 
            "safety_issue": "No", 
            "time_frame": "Day 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816503"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The mean pain intensity the patient experienced over the last 24 hours will be measured through Numeric Rating Scale (NRS); 0 = no pain, 10 = worst pain imaginable.", 
                "measure": "The change from baseline in pain intensity", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to Day 10"
            }, 
            {
                "description": "Karnofsky Performance Status Rating Scale is a tool to assess cancer patients' physical functioning. Scores range from 0 per cent  (dead) to 100 per cent  (normal, no complaints, no evidence of disease) in a unit of 10 per cent to indicate a level of overall daily activity performance status.", 
                "measure": "The change from baseline in Karnofsky Performance Status Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 10"
            }, 
            {
                "description": "Patients indicate in a Numeric Rating Scale (NRS) the number of awakening from sleep due to pain in the previous night: not awakened, once, twice, more than 3 times, or could not sleep.", 
                "measure": "Sleep disturbance caused by the number of awakening caused by pain the patient experienced over the last night", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "description": "Patients indicate in a Numeric Rating Scale (NRS) the sleep disturbance caused by pain experienced over the last 24 hours, where 0= not disturbing at all, and 10= very disturbing.", 
                "measure": "Sleep disturbance caused by pain the patient experienced over the last 24 hours", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "description": "CGI-I measures the overall improvement of the patient's condition compared to baseline, as follows; 1 = Improved very much, 2 = Improved a lot, 3 = Improved a little, 4 = No change, 5 = Aggravated a little, 6= Aggravated a lot, 7= Aggravated very much.", 
                "measure": "The change from baseline in Clinical Global Impression - Improvement (CGI-I)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 10"
            }, 
            {
                "description": "This tool assesses how effective the study drug has been in pain treatment during the study period. The patient will assess the effectiveness from his/her viewpoint at visit 10 on a 5-point rating scale; 1 = not effective, 2 = fair, 3 = effective, 4 = very effective, 5 = very much effective.", 
                "measure": "Patient's Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "This tool assesses how effective the study drug has been during the study period. The investigator will assess the effectiveness from his/her viewpoint at Visit 10 on a 5-point rating scale; 1 = not effective, 2 = fair, 3 = effective, 4 = very effective, 5 = very much effective.", 
                "measure": "Investigator's Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "The dose of fentanyl matrix used throughout the study.", 
                "measure": "Dose of fentanyl matrix", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}